trending Market Intelligence /marketintelligence/en/news-insights/trending/stio__y67ig5q8x5pmt57g2 content esgSubNav
In This List

Aurinia Pharmaceuticals appoints director

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Aurinia Pharmaceuticals appoints director

Canada's Aurinia Pharmaceuticals Inc. added Michael Hayden to its board.

Hayden most recently served as president of global research and development and chief scientific officer at Teva Pharmaceutical Industries Ltd.